Drug Guide
Vasopressin
Classification
Therapeutic: Vasopressor, Antidiuretic hormone
Pharmacological: Vasopressin receptor agonist
FDA Approved Indications
- Treatment of vasodilatory shock, including septic shock; Diabetes insipidus; Cardiac arrest (as an adjunct)
Mechanism of Action
Vasopressin acts on V1 receptors on vascular smooth muscle to cause vasoconstriction, and on V2 receptors in the kidney's collecting ducts to promote water reabsorption, reducing urine volume.
Dosage and Administration
Adult: Typically, IV infusion of 0.01 to 0.04 units/min; dosing should be titrated based on clinical response.
Pediatric: Dosing varies; generally administered IV infusion with doses adapted to weight and clinical response. Consult specific pediatric dosing guidelines.
Geriatric: Use with caution; adjust doses as needed, considering cardiac and vascular status.
Renal Impairment: Dose adjustment may be necessary; monitor closely.
Hepatic Impairment: No specific adjustment recommended; use cautiously.
Pharmacokinetics
Absorption: Administered IV; bioavailability is 100%.
Distribution: Widely distributed; crosses the blood-brain barrier minimally.
Metabolism: Metabolized in the liver and kidneys.
Excretion: Excreted mainly unchanged in urine.
Half Life: Approximately 10-20 minutes.
Contraindications
- Vasopressin allergy or hypersensitivity
Precautions
- Use cautiously in patients with coronary artery disease, hyponatremia, or vascular disease; monitor fluid balance and electrolytes closely.
Adverse Reactions - Common
- Nausea (Uncommon)
- Abdominal cramps (Uncommon)
- Hypertension (Uncommon)
Adverse Reactions - Serious
- Ischemic events (myocardial infarction, angina, arrhythmias) (Rare)
- Hyponatremia leading to seizures or coma (Rare)
Drug-Drug Interactions
- Sympathomimetics may increase vasoconstriction; diuretics can alter fluid balance.
Drug-Food Interactions
N/ADrug-Herb Interactions
N/ANursing Implications
Assessment: Monitor blood pressure, heart rate, serum sodium, urine output, and signs of ischemia.
Diagnoses:
- Risk for fluid imbalance
- Ineffective tissue perfusion
Implementation: Administer as ordered; monitor for adverse effects; ensure adequate hydration.
Evaluation: Assess response to therapy; monitor for signs of adverse reactions.
Patient/Family Teaching
- Report chest pain, numbness, or tingling; sit or lie still when receiving IV infusion; report signs of hyponatremia such as nausea or confusion.
Special Considerations
Black Box Warnings:
- Vasopressin should be used cautiously due to risk of severe ischemic events and hyponatremia.
Genetic Factors: N/A
Lab Test Interference: May affect serum sodium and other electrolyte tests.
Overdose Management
Signs/Symptoms: Severe hypertension, bradycardia, ischemic events, or hyponatremia.
Treatment: Discontinue vasopressin; provide supportive care; treat hyponatremia with careful correction; manage hemodynamic instability.
Storage and Handling
Storage: Store at room temperature, protected from light.
Stability: Stable for the duration specified in the package insert, typically 24 months.